NNG-DEPO vs Pegmolesatide (HS-20039)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline

NNG-DEPO · Stimus

Developed by Nanogen Pharmaceutical Biotechnology

Phase 3 in Chronic Kidney Diseasebiologic (registry-typed, subtype undisclosed)
Partial signal

NCT05585645 · Phase 3 · completed

The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.

No aligned efficacy figure on record for this race.

Pegmolesatide (HS-20039)

Marketed by Hansoh Pharmaceutical Group

Phase 3 in Chronic Kidney Diseasebiologic (pegylated EPO-mimetic peptide)
Reliable signal

NCT03902691 · Phase 3 · completed

This randomized, double-blind trial compared pegmolesatide directly against an active comparator, epoetin alfa, rather than placebo. Its prespecified non-inferiority comparison on hemoglobin change was met, with the between-group difference confidence interval falling entirely within the specified margin.

Next expected readout: December 2026 · NCT06946394 (registry estimate)

Reported efficacy

The mean change from the baseline hemoglobin level to the mean level during the evaluation period (Week 17-24): Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L (met)

Result source: NCT03903809

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNNG-DEPOPegmolesatide (HS-20039)
Kidney composite outcome—Not posted · NCT05585645—Not posted · NCT03902691
UACR, % change—Not posted · NCT05585645—Not posted · NCT03902691
eGFR slope—Not posted · NCT05585645—Not posted · NCT03902691
Haemoglobin, change—Not posted · NCT055856450.1 vs -0.2avs epoetin alfaNCT03902691

Kidney composite outcome

NNG-DEPO
—Not posted · NCT05585645
Pegmolesatide (HS-20039)
—Not posted · NCT03902691

UACR, % change

NNG-DEPO
—Not posted · NCT05585645
Pegmolesatide (HS-20039)
—Not posted · NCT03902691

eGFR slope

NNG-DEPO
—Not posted · NCT05585645
Pegmolesatide (HS-20039)
—Not posted · NCT03902691

Haemoglobin, change

NNG-DEPO
—Not posted · NCT05585645
Pegmolesatide (HS-20039)
0.1 vs -0.2avs epoetin alfaNCT03902691
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNG-DEPO: no structured comparison results are available for Chronic Kidney Disease.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pegmolesatide (HS-20039)

Hemoglobin Change g/dL 0.07 vs -0.22 epoetin alfa g/dL
absolute change · g/dL
NCT03902691 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNG-DEPO's landscape · Pegmolesatide (HS-20039)'s landscape